Strategic Minerals PLC (LON:SML) highlighted the world class potential of the Redmoor project as it revealed a new mineral resource estimate. It was estimated that Redmoor contains some 137,000 tonnes of inferred tin resources, up from 45,000 tonnes.
Medical imaging specialist Feedback PLC (LON:FDBK) has appointed Dr Tom Oakley as the chief executive of its Feedback Medical operating subsidiary.
Redx Pharma Plc (LON:REDX) said that, further to its announcement of 19 November 2018, James Mead assumed his new role as chief financial officer on 1 February 2019 The company also announced that on 13 February 2019, options over 1,200,000 ordinary shares in the company, were granted to Mead.
SkinBioTherapeutics PLC (LON:SBTX) said Dr Cath O'Neill will be “transitioning” from her role as chief executive this year with the life sciences company looking for a “commercially experienced individual” to succeed her.
Cabot Energy PLC (LON:CAB) told investors that it will use a new moratorium on Italian exploration activities as an opportunity to evaluate its future strategy in the country. Italy earlier this week introduced a pause of up to 18 months on all work on oil and gas exploration permits or applications to allow a review as part of the ‘Plan for Sustainable Energy Transition of Suitable Areas’ (PTESAI) bill.
Global healthcare and life sciences company Arix Bioscience PLC (LON:ARIX) said Harpoon Therapeutics, one of its portfolio companies, has completed its flotation on NASDAQ. Harpoon, a clinical-stage immunotherapy company developing a novel class of T cell engagers, completed an initial public offering (IPO) of 5.4mln shares at US$14 a shot, raising US$75.6mln.
Motif Bio Plc (LON:MTFB) (NASDAQ:MFTB) said it has requested a meeting with the Food & Drug Administration after the US watchdog said it wouldn’t be giving the regulatory green light to the company’s antibiotic, iclaprim. In what’s called a complete response letter, the FDA indicated additional data would be required “to further evaluate the risk for liver toxicity” before granting approval.
Fund manager Tavistock Investments PLC (LON:TAVI) reiterated its commitment to pay a maiden dividend this fiscal year despite trading being below expectations. The company said that funds under management (FUM) and earnings are still expected to grow significantly in the year to the end of March, albeit not as rapidly as management had hoped.
NetScientific PLC revealed that its portfolio company Glycotest Inc. has received the initial US$3mln tranche of the US$10mln Series A financing round with Shanghai Fosun Pharmaceutical Co. Ltd. , a leading healthcare group based in China. It added that funding of the remaining US$7mln is due on completion of certain milestones.
Africa-focused property investor GRIT Real Estate Income Group Limited (LON:GR1T) expects to meet its income targets though property conditions in its markets aren’t easy. "Given the strength of the Group’s existing portfolio, the Company expects to continue to deliver annual rental growth as well as possible capital value increases through yield compression," said Bronwen Corbett, chief executive.
IronRidge Resources Limited (LON:IRR) said it had secured access rights for a “highly prospective” gold license application to the Zaranou project in Côte d'Ivoire. Big Pic in December.
Vast Resources PLC announced that it has been appointed venture partner by the Chiadzwa Community Development Trust which has, in principle, been granted the right to mine diamonds on the Heritage Concession, Block T1A of the Marange Diamond Fields in Zimbabwe.
Futura Medical PLC (LON:FUM) said it will host its first European Key Opinion Leader (KOL) Advisory Panel meeting ahead of the 21st Congress of the ESSM on 14-16 February 2019, at Cultural and Congress Centre Cankarjev Dom, Ljubljana, Slovenia. This meeting follows the successful US KOL Advisory Panel meeting at the Sexual Medicine Society of North America (SMSNA) in November 2018.
DP Poland Plc (LON:DPP) announced that it has conditionally raised additional gross proceeds of approximately £0.5mln via the Broker Option in its fundraising announced on 7 February. The group said an additional 8,333,333 new ordinary shares were placed by Peel Hunt at a price of 6p each, with significant demand via the Broker Option and the book over-subscribed.
Galantas Gold Corporation (LON:GAL) (TSX:GAL) said it has awarded 3,200,000 incentive stock options to directors, officers, consultants and key employees. The group said the exercise price for the options, which expire on February 13, 2024, is C$0.09 per share.